research grade peptide FAQ

For same-day use in cell culture or in vivo administration, sterile saline (0.9% NaCl) or phosphate-buffered saline (PBS, pH 7.4) are acceptable alternatives that avoid benzyl alcohol exposure. Prepare only the volume needed for that day's experiments and discard any unused solution. Saline lacks the antimicrobial preservative (benzyl alcohol) that allows bacteriostatic water to remain sterile for weeks. For longer storage, bacteriostatic water remains the standard, but verify the pH is 7.2–7.6 before reconstitution. If your application requires DMSO for membrane permeability studies, reconstitute at ≤10% DMSO final concentration and test stability at your specific storage temperature before committing to a full protocol.

Published EC50 values for Dihexa in neurogenesis assays range from 10 nM to 1 µM depending on the cell model, assay duration, and serum content in the medium. If your EC50 is consistently 5–10× higher than published values using the same cell line, suspect peptide degradation during storage or reconstitution. Prepare a fresh stock from a newly opened vial, reconstitute in DMSO under anhydrous conditions, and run a side-by-side comparison with your existing stock. Also verify that your assay endpoint (BrdU incorporation, Ki67 staining, neurite outgrowth) matches the published protocol. Different endpoints detect different phases of neurogenesis and yield different potency curves.

First, verify peptide concentration: weigh the reconstituted solution to confirm volume, then back-calculate concentration assuming complete dissolution. Lyophilized peptides often include cryoprotectants (mannitol, trehalose) that add 5–15% to the stated peptide mass. If you reconstituted 50mg stated mass in 10ml water to achieve "5mg/ml," the actual concentration may be 4.3–4.7mg/ml depending on cryoprotectant content. Second, confirm storage conditions matched the reference study. Dihexa stored at room temperature for three weeks is not equivalent to freshly reconstituted peptide, even if both appear clear. Third, compare synthesis methods if the supplier discloses them: solid-phase peptide synthesis (SPPS) using Fmoc chemistry is the standard for Dihexa, but some suppliers use liquid-phase synthesis that introduces different impurity profiles.

Purity percentage alone doesn't indicate what the remaining 1–3% contains. A 99% pure peptide with 1% deletion sequences (missing one amino acid) will underperform a 97% pure peptide where the 3% is residual TFA salt (biologically inert but adds mass). Request the full HPLC chromatogram and check for secondary peaks. Any peak above 1% of the main peak area represents a synthesis impurity. Additionally, verify the molecular weight via mass spectrometry matches the theoretical mass for intact Dihexa (559.73 g/mol for the free base). A mass discrepancy of ±14 Da or more suggests structural modification that would impair c-Met binding.

Contact the supplier immediately with photographic documentation and request batch replacement. Lyophilized IGF-1 LR3 can tolerate brief ambient temperature exposure (up to 72 hours at <25°C), but you cannot verify exposure duration during shipping. Request temperature log data if the supplier uses monitored shipping—any excursion above 30°C or total ambient exposure exceeding 96 hours likely compromised peptide stability. Suppliers refusing replacement for documented temperature failures are not operating at research-grade standards.

Never mix peptides in the same syringe unless chemical compatibility data explicitly confirms stability. Peptide-peptide interactions can cause aggregation, altered activity profiles, or complete inactivation. Administer each compound separately using individual syringes, spacing injections by 5–10 minutes and using different anatomical sites to prevent localized concentration effects. For research models requiring frequent multi-peptide administration, consider staggered dosing schedules (morning vs evening) to reduce handling stress and injection site reactions. Our research teams working with complex peptide stacks like Epithalon Peptide combined with Thymalin maintain separate administration protocols with documented timing intervals for this exact reason.

Increase peptide concentration during reconstitution to allow larger injection volumes while maintaining target dose. A 5mg Pinealon vial reconstituted with 0.5mL bacteriostatic water yields 10mg/mL concentration. A 50mcg dose requires only 0.005mL (5 microliters), which exceeds precision limits of standard insulin syringes. Reconstituting the same vial with 2mL yields 2.5mg/mL, making the 50mcg dose achievable with 0.02mL (20 microliters). Still challenging but within capable range using 0.3mL insulin syringes with 0.01mL graduations. For ultra-low doses below this threshold, serial dilution techniques using additional bacteriostatic water allow accurate measurement, though each dilution step introduces additional contamination risk.

Verify that the supplier maintains retained samples from every batch for minimum two years and can provide comparative purity data across sequential batches. Request a formal quotation covering projected volumes with pricing stability and guaranteed availability. For longitudinal research, you need assurance that peptides purchased in year three match the validated batch from year one. Some suppliers offer custom synthesis runs for large research programs, ensuring that all peptide used throughout the study comes from a single master batch, eliminating batch-to-batch variability entirely.

This is a critical documentation failure. Do not use the peptide until you receive a batch-matched COA. Generic certificates mean the supplier is not testing every batch individually, which creates risk that your specific vial contains deletion sequences, oxidation products, or contamination not reflected in the provided data. A batch-matched COA is not a premium service—it's a minimum standard for research-grade peptides. If the supplier cannot provide it, they're not maintaining pharmaceutical-grade documentation practices.

Verify reconstitution solvent compatibility with your assay. DMSO concentrations above 0.5% in culture medium can independently suppress neural progenitor proliferation or induce differentiation, masking Dihexa's HGF-mediated effects. Dilute DMSO stocks to <0.1% final concentration or switch to bacteriostatic water for reconstitution. Second, confirm your c-Met receptor expression in the cell line being used. Dihexa's mechanism requires functional c-Met on neural progenitors, and some immortalised cell lines downregulate receptor expression after extended passage. Running a Western blot for c-Met or an HGF binding assay can rule out receptor absence as the null result cause.

Contact the supplier immediately and request the temperature log from the shipment before using the product. If the internal package temperature remained below 8°C for the entire transit period (verified by data logger), the peptide is likely unaffected even if the ice packs melted. The log proves the thermal mass kept the interior cool. If the log shows excursions above 8°C for more than 4 hours cumulatively, request a replacement. Do not attempt to "test" the peptide by using it in a pilot experiment. Degraded Dihexa produces unpredictable dose-response curves that will confound your protocol from the start.

Discard immediately and do not administer. Visible aggregation indicates peptide denaturation or microbial contamination, both of which compromise experimental validity. Dihexa should form a clear, colorless solution upon reconstitution with bacteriostatic water. Cloudiness within 48 hours suggests the lyophilized powder was exposed to humidity before reconstitution, causing partial hydrolysis. Cloudiness after seven days indicates bacterial growth despite bacteriostatic water. The vial was contaminated during reconstitution and must be replaced.

Verify peptide integrity before concluding the protocol failed. Request ESI-MS analysis of the remaining peptide solution to confirm molecular weight matches the theoretical Dihexa mass (738.5 Da for the free base). If mass spec shows degradation products or incorrect mass, the issue was peptide quality, not protocol design. If mass spec confirms intact peptide, consider dosing frequency: switch from once-daily to twice-daily administration to maintain steady-state c-Met receptor occupancy, as the peptide's 4–6 hour brain half-life creates trough periods with single daily dosing.

No. Reconstitute only the amount needed for 7–10 days of experiments if using bacteriostatic water (refrigerated at 2–8°C), or prepare a high-concentration DMSO stock (10–50 mM), aliquot into single-use volumes, and store at −20°C. Repeated pipetting from a single vial introduces contamination risk and repeated temperature fluctuations that degrade peptide over time. For large-scale studies requiring 50+ mg total, order multiple smaller vials (5–10 mg each) rather than one 50 mg vial. This preserves the majority of your stock in unopened, lyophilised form until needed.

This is a critical red flag indicating either a labeling error or intentional misrepresentation. Email the supplier with photos of both the vial label and the CoA, and request clarification before opening the product. Reputable suppliers maintain strict lot traceability. Every vial should trace to a specific synthesis batch with a corresponding CoA generated within 30 days of synthesis. If the supplier cannot provide a matching CoA or claims the batch numbers "don't need to match," do not use the product and consider switching suppliers. Batch traceability is non-negotiable for research-grade peptides.

This indicates batch-to-batch variability, which is the most common failure mode for mid-tier suppliers. Request retained sample testing comparing the two batches—a professional supplier can provide comparative HPLC and MS data showing whether purity or sequence fidelity differed. If the supplier cannot provide this data, switch to a vendor offering small-batch synthesis with verified consistency. Batch variability is unacceptable in dose-response research, receptor binding studies, or any protocol requiring reproducibility across multiple experimental runs.

Discard the vial and request replacement with verified cold-chain shipping. Lyophilized peptides exposed to temperatures above 30°C during transit undergo partial degradation that HPLC testing at the destination laboratory cannot reverse. Even if the powder appears normal, heat exposure denatures peptide bonds at the molecular level. Using compromised peptides introduces uncontrolled variables into research protocols that invalidate comparative studies. Legitimate suppliers replace temperature-compromised shipments at no cost; refusal to do so confirms the supplier lacks quality assurance infrastructure.

Aliquot the reconstituted solution into single-use amber glass vials immediately after mixing and store at −80°C. Freezing arrests oxidation and deamidation reactions that degrade the peptide in aqueous solution. Thaw each aliquot only once, immediately before administration. Do not refreeze. This approach maintains potency for 90–120 days. Alternatively, store the peptide as lyophilized powder at −20°C and reconstitute fresh aliquots weekly, which eliminates freeze-thaw cycles entirely.

Do not use it. Request replacement with documented cold-chain logs. Lyophilized peptides exposed to temperatures above 30°C for more than four hours undergo partial racemization that HPLC cannot detect but that abolishes biological activity. The visual appearance remains unchanged. White powder. But potency may be reduced by 20–50%. Using degraded peptide introduces a confounding variable that makes null results uninterpretable: you cannot determine whether the protocol failed or the peptide was inactive.

Verify three factors: peptide purity and sequence accuracy (request CoA), reconstitution concentration calculations, and dosing administration route. Published PE-22-28 research uses specific dosing ranges and administration methods—subcutaneous injection produces different pharmacokinetics than intraperitoneal. Additionally, confirm your animal model matches the species and strain used in the reference study; neuroinflammatory responses vary significantly across rodent strains. If all protocol variables align but results still differ, peptide degradation during storage or handling is the most likely cause.